Efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with ribavirin for the treatment of HCV genotype 1b compensated cirrhosis in patients aged 70 years or older. [electronic resource]
Producer: 20180212Description: e9271 p. digitalISSN:- 1536-5964
- 2-Naphthylamine
- Aged
- Aged, 80 and over
- Anilides -- therapeutic use
- Antiviral Agents -- therapeutic use
- Carbamates -- therapeutic use
- Cyclopropanes
- Drug Resistance, Viral
- Drug Therapy, Combination
- Female
- Genotype
- Hepatitis C, Chronic -- drug therapy
- Humans
- Lactams, Macrocyclic
- Liver Cirrhosis -- drug therapy
- Macrocyclic Compounds -- therapeutic use
- Male
- Proline -- analogs & derivatives
- Prospective Studies
- Ribavirin -- therapeutic use
- Ritonavir -- therapeutic use
- Sulfonamides -- therapeutic use
- Sustained Virologic Response
- Uracil -- analogs & derivatives
- Valine
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.